

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Ipilimumab (genetical recombination)

October 12, 2022

Therapeutic category

Other antitumor agents

Non-proprietary name

Ipilimumab (genetical recombination)

Safety measure

Precautions should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision
<p>8. IMPORTANT PRECAUTIONS (N/A)</p> <p>11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)</p>	<p>8. IMPORTANT PRECAUTIONS <u>Uveitis may occur. Whether ocular abnormalities have occurred should be examined periodically. In addition, patients should be instructed to immediately seek medical attention if any ocular abnormalities are observed.</u></p> <p>11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Uveitis</u></p>

(N/A) Not Applicable. No corresponding language is included in the current Precautions.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp